{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.2","upperLimit":"54.6","value":"35.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"The percentage of participants with documented best overall response of Very Good Partial Response (VGPR) or better (VGPR, Complete response \\[CR\\], or Stringent complete response \\[sCR\\]) per 2016 standard International Myeloma Working Group (IMWG) criteria was computed.","dispersionType":"95% Confidence Interval","groups":[{"description":"The Phase 2 cohort further explored the efficacy of venetoclax in combination with dexamethasone in relapsed or refractory participants with t(11;14) translocation multiple myeloma. Participants received daily venetoclax at a dose of 800 mg (no lead-in period) on Days 1- 21 of each cycle concomitant with weekly dexamethasone at a dose of 40 mg (20 mg for those aged ≥ 75 years).","id":"OG000","title":"Phase 2 Expansion: Venetoclax 800 mg/Dexamethasone 20 or 40 mg"}],"paramType":"NUMBER","populationDescription":"All enrolled Phase 2 participants who received venetoclax and had active disease at baseline; primary efficacy endpoints were pre-specified for Phase 2 only, and are reported for all participants with available data","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, and on Day 1 of every cycle thereafter; estimated median time on follow-up was 31.7 months","title":"Phase 2: Very Good Partial Response Rate or Better","type":"PRIMARY","unitOfMeasure":"percentage of participants"}